Atherosclerosis and Cardiovascular Disease

1 Cholesterol-CHD connection: evidence for the benefit of lipoprotein modification.- Epidemiological Studies on Atherosclerosis and Coronary Heart Disease.- 2 The effect of coronary heart disease prevention on the prevention of non-cardiovascular diseases.- 3 The meaning and relevance of intervention trials in prevention.- 4 Prospects for primary prevention of coronary heart disease.- 5 Dyslipemia in Portugal.- 6 The Brisighella study: plasma lipid trend in the elderly observed over a twelve year period.- Genetics of Coronary Heart Disease and Atherosclerosis: Clinical and Epidemiological Implications.- 7 FH gene phenotypic expression: insight for therapeutic strategy.- 8 Development of coronary heart disease in familial hypercholesterolemia.- 9 Effect of genes on levels and variability of risk factors for coronary heart disease.- 10 The type of mutation in apolipoprotein E determines whether type III hyperlipoproteinemia is expressed as a dominant or recessive trait.- The Vegetative Nervous System and Cardiovascular Disease.- 11 The sympatho-vagal balance and arterial hypertension.- 12 The autonomic disturbance accompanying myocardial infarction.- 13 The vegetative nervous system and atrial natriuretic factor.- Nosology of Hyperlipoproteinemias.- 14 Apolipoproteins and metabolism in atherosclerosis.- 15 Lipoprotein(a) and the LDL receptor (LDL-R): examination of the problem in a pedigree of rhesus monkeys with a familial hypercholesterolemia secondary to LDL-R deficiency.- 16 Clinical significance of apolipoprotein B containing lipoprotein particles.- 17 Hyperlipoproteinemia of lipoprotein Lp(a).- 18 LDL and atherosclerosis: from quantity to quality.- 19 Lipid distribution in human coronary lesions: analysis by digital imaging microscopy.- Nutrition: Population Studies.- 20 Time trends of risk factors for coronary heart disease in southern Italy.- 21 Nutritional aspects in the C.N.R. ‘D.I.S.CO.’ Project.- 22 Nutrition habits in a free living community: the Brisighella study.- Nutrition: Special Diets and Metabolic Effects of Fats and Proteins.- 23 Experimental atherosclerosis: anomalous fats.- 24 Cholesterol-lowering action of diets rich in polyunsaturated fatty acids.- 25 Receptor-mediated catabolism of LDL in rabbits fed cholesterol-free, semipurified diets containing casein or soy protein: a time-course study.- 26 The effects of monounsaturated fatty acids on serum lipoprotien levels in healthy adult volunteers.- 27 Olive oil in nutrition and in prevention.- Athersclerosis, Computer Handling Studies and Mathematical Modelling.- 28 Some methods for medical image processing using supercomputers.- 29 A diffusion-governed model related to atheroma deposition.- 30 Mathematical model: interpolation and simulation.- 31 Limits of mathematical models in biology and medicine.- 32 The application of Markov process approach for the description of atherosclerotic phenomena.- 33 Utility and limits of a Markov birth process in the study and simulation of the atheroma evolution.- New Perspectives in the Treatment of Hypercholesterolemia and the Prevention of Atherosclerosis.- 34 Modification of lipoproteins in the intimai extracellular compartment that can contribute to atherogenesis.- LDL Apheresis: Efficacy Versus Ethical and Social Aspects.- 35 LDL apheresis: current situation in Japan.- 36 The effect of LDL-apheresis on some hemostatic parameters in homozygous familial hypercholesterolemia.- Developments in Lipoprotein and Apoprotein Research.- 37 Regulation of VLDL metabolism by cellular receptors.- 38 Current concepts in reverse cholesterol transport.- 39 Regulation of hepatic lipoprotein biosynthesis by hormones.- 40 Postprandial lipemia in patients with coronary artery disease.- 41 Lipid transport between plasma lipoproteins and cells: physicochemical regulation of lipid transfer rates and the secretion of very low density lipoproteins.- Thrombosis and Atherosclerosis: Clinical Insights.- 42 Hypercholesterolemia and haemostatic function changes.- 43 Predictive value of fibrinogen in arterial thrombosis.- Glycosaminoglycans and their Clinical Implications.- 44 Glycosaminoglycans and the proliferation of arterial smooth muscle cells.- Calcium Antagonists and Atherosclerosis.- 45 Do calcium antagonists inhibit atherogenesis?.- 46 Atherosclerosis-related effects of verapamil, anipamil and other calcium antagonists studied on cell culture.- 47 Antiatherosclerotic effects of anipamil, verapamil and other calcium antagonists studied on cell culture.- 48 Can the progression of coronary heart disease be influenced by calcium antagonists?.- Atherosclerosis Regression from a Clinical and Anatomo-Pathological Standpoint.- 49 A five year follow up of carotid atherosclerosis using B-mode imaging ultrasound.- 50 Preliminary results of the program on the surgical control of the hyperlipidemias (POSCH).- 51 The time course of atherosclerotic lesion regression in macaque monkeys.- 52 Human atherosclerosis and inflammation. An immunocytochemical and ultrastructural investigation.- 53 Carotid plaque volume measurement.- 54 Humoral factors of direct influence on the formation and regression of atheromatous plaques.- Atherosclerosis in Youth.- 55 The WHO-ISFC study on pathobiological determinants of atherosclerosis in youth (PBDAY): a first morphometric approach to aortic lesions.- 56 Atherosclerosis precursors in children. The Bologna study, an update.- 57 Lipid and apolipoprotein in cord blood.- New Lipid Lowering Agents.- 58 Probucol revisited.- 59 Controlled US studies of fenofibrate in the treatment of dyslipidemias.- 60 Effect of trapidil and its derivatives on the receptor-mediated low density lipoprotein metabolism by cultured human hepatic and extrahepatic cells.- 61 Bezafibrate: effects on serum lipoproteins and haemostatic factors.- LDL Apheresis.- 62 Efficiency and efficacy of LDL-apheresis performed at different intervals.- 63 Ischemic heart disease and plasmapheresis for cholesterol.- 64 Variables involved in the treatment of severe hyperlipoproteinemias by combined drug and LDL-apheresis treatment.- 65 Multiple effects of LDL-apheresis against progression of atherosclerosis in patients with familial hypercholesterolemia.- 66 Long-term LDL apheresis in FH.- 67 Long-term double filtration LDL-apheresis in familial hypercholesterolemia.- Standardization of Apoprotein Measurement in Blood.- 68 Apolipoprotein profile of a sample of Italian population. Correlations with coronary risk factors.- 69 A survey on apolipoprotein A-l and B: the CNR study.- 70 Reference standard for cholesterol evaluation in serum obtained by isotope dilution mass spectrometry.- Cardiologists and CHD and Atherosclerosis Prevention Versus Therapy.- 71 Incidence and prognostic significance of silent myocardial ischemia in patients after acute myocardial infarction.- 72 Chronic ischemic heart disease: prevention and therapy.- 73 Cholesterol and coronary heart disease — the pros and cons for action.- 74 Diagnosis and evaluation of ischemic heart disease.- 75 Antioxidant metabolic mechanisms in hypertensive and atherosclerotic arterial wall.- 76 Magnetic resonance of the heart.- 77 The role of HDL-subfractions in reverse cholesterol transport and its disturbances in tangier disease and HDL-deficiency with xanthomas.- Rationale for Prevention in High Risk Subjects.- 78 HDL cholesterol and triglycerides as risk factors for CHD.- 79 The ATS-Sardegna prevention campaign. Background and features.- 80 The Brisighella heart study report from 1984 to 1989.- Hyperlipoproteinemia Therapy: When to Opt for Drug Combinations.- 81 Drug combination therapy for selected hyperlipidemic patients.- 82 Hyperlipoproteinemia therapy: when to opt for drug combination?.- 83 Combined Pharmacological treatment of heterozygous familial hypercholesterolemia.- Hypertension as a Risk Factor.- 84 Review of primary prevention trials of antihypertensive treatment.- 85 Hypertension: why a risk factor for atheroscolerosis?.- 86 Hypertension in the elderly.- Invasive Therapy of Coronary and Cerebrovascular Diseases.- 87 Coronaric and cerebral ischemia: surgery in one or two stages.- 88 Invasive monitoring of coronary blood flow in acute myocardial infarction: pathogenetic and therapeutic relevance.- 89 Prevention of stroke in bilateral carotid lesions.- 90 The role of percuraneous transluminal coronary angioplasty (PTCA) in the treatment of clinical syndromes of coronary atherosclerosis.- 91 Invasive treatment of acute stroke.